Acta Scientific Pharmaceutical Sciences (ISSN: 2581-5423)

Volume 8 Issue 10 October 2024

Review Article

Pharmacological Interventions and Emerging Therapies in the Management of Obesity

Adinarayana Andy[1]*, Divya Andy[2] and Aman Suresh Tharayil[3]

[1]*Pharmacy Manager Weatherwax Family Pharmacies Inc Spring Arbor, Michigan, USA*

[2]*Independent Research Consultant, Michigan, USA*

[3]*Assistant Professor, Department of Pharmacy Practice, Sandip Institute of Pharmaceutical Sciences, Nashik, Maharashtra, India*

***Corresponding Author:** Adinarayana Andy, Pharmacy Manager Weatherwax Family Pharmacies Inc Spring Arbor, Michigan, USA.

Received: September 24, 2024

Published: September 29, 2024

Abstract

Obesity is a complex, chronic condition characterized by an excessive accumulation of body fat, defined by a Body Mass Index (BMI) of 30 or higher. It is a growing global health issue linked to numerous health complications, including type 2 diabetes, cardiovascular diseases, and certain cancers. The prevalence of obesity has escalated significantly in recent decades, affecting individuals of all ages and backgrounds. Its multifactorial causes range from genetic and environmental factors to behavioral and psychological influences. While lifestyle changes are central to obesity management, pharmacological interventions are increasingly being explored to enhance weight loss efforts. This paper explores the epidemiology, pathogenesis, and current pharmacological approaches to obesity management, including emerging treatments that offer new hope in the fight against this global epidemic.

Keywords: BMI; Obesity; Weight Loss

Introduction

Obesity is a complex, multifactorial chronic disease that has become a major global health concern [1]. Characterized by an excessive accumulation of body fat, obesity is defined by a Body Mass Index (BMI) of 30 or higher (Table 1) [2]. This condition is not merely a cosmetic issue but a serious medical concern associated with a wide range of health complications, including type 2 diabetes, cardiovascular diseases, certain types of cancer, and increased mortality [3].

The prevalence of obesity has risen dramatically over the past few decades, affecting individuals across all age groups and socioeconomic backgrounds. According to the World Health Organization (WHO), more than 1.9 billion adults worldwide were overweight in 2016, with over 650 million classified as obese [4]. This trend shows no signs of abating, with obesity rates continuing to climb in both developed and developing nations.

The causes of obesity are multifactorial, involving an interplay of genetic, environmental, psychological, and behavioral factors. Sedentary lifestyles, poor dietary habits, and the widespread availability of high-calorie, nutrient-poor foods have contributed significantly to the obesity epidemic [5]. Additionally, factors such as genetics, hormonal imbalances, and certain medications can predispose individuals to weight gain.

Obesity poses a substantial burden on healthcare systems, with associated medical costs and productivity losses running into billions of dollars annually [6]. Beyond its physical health implications, obesity also has a profound impact on mental health, often leading to stigmatization, low self-esteem, and depression.

Given the complexity of obesity and its far-reaching consequences, effective management requires a multifaceted approach. This typically includes lifestyle interventions, behavioral therapy, and in many cases, pharmacotherapy or bariatric surgery. However, the challenges of sustained weight loss and the prevention of weight regain make obesity a difficult condition to manage long-term.

In response to the growing obesity crisis, there has been significant interest in the development of pharmacological treatments that can aid in weight loss. These medications offer an additional tool for individuals who struggle to achieve and maintain weight loss through lifestyle modifications alone [7]. As research continues to advance, new weight loss drugs are emerging, providing hope for more effective and sustainable obesity management.

Table 1: Proposed Classification of Weight by BMI in Adult Asians.

BMI (Kg/m^2)	Classification	Risk of co-morbidity
< 18.5	Underweight	Minimal (but higher chance of other clinical issues)
18.5-22.9 > 23	Normal range	Average
23-24.9	Overweight At risk	Increase
25-29.9	Obese I	Moderate
> 30	Obese II	Severe



Figure 1: Classification of BMI.

Epidemiology of obesity

Obesity is a significant public health concern with a rising global prevalence. According to the World Health Organization (WHO), more than 1.9 billion adults were overweight in 2016, with over 650 million of them classified as obese [4]. The prevalence of obesity has nearly tripled since 1975. In the United States, the Centers for Disease Control and Prevention (CDC) reports that 42.4% of adults were obese in 2017-2018, up from 30.5% in 1999-2000 [8]. Obesity rates are also increasing among children and adolescents, with 19.3% of U.S. youth affected in 2017-2018 [9]. This condition is associated with numerous health risks, including cardiovascular diseases, type 2 diabetes, and certain cancers, leading to increased mortality and a substantial economic burden on healthcare systems.

Pathogenesis of obesity

The pathogenesis of obesity is a complex process involving multiple factors, including genetic, environmental, and physiological influences.

Genetic factors

Heritability

Obesity tends to run in families, suggesting a strong genetic component. Genes can influence the storage and distribution of body fat, the rate of metabolism, and appetite regulation [10].

Monogenic forms

Rare genetic conditions, such as mutations in the leptin or leptin receptor gene, can cause severe obesity [11].

Polygenic obesity

Most cases of obesity are polygenic, where multiple genes contribute small effects that collectively increase susceptibility to obesity [12].

Environmental factors

Diet

High-calorie diets, particularly those rich in fats and sugars, contribute to energy imbalance and weight gain.

Physical inactivity

Sedentary lifestyles, influenced by modern conveniences, reduce energy expenditure and promote weight gain.

Socioeconomic status

Lower socioeconomic status is often associated with limited access to healthy foods and opportunities for physical activity.

Physiological factors

Energy homeostasis

The body's energy balance is regulated by a complex interaction between the central nervous system, peripheral organs, and hormonal signals. Dysregulation in these systems can lead to an imbalance between energy intake and expenditure [13].

Hormonal influences

Hormones like insulin, ghrelin, leptin, and cortisol play significant roles in hunger, satiety, and fat storage. For example, leptin resistance is commonly observed in obese individuals, where the body does not respond appropriately to the satiety signals from leptin [14].

Adipose tissue dysfunction

Adipose tissue is not just a storage depot for fat but also an active endocrine organ that secretes various adipokines, which influence inflammation, insulin sensitivity, and energy metabolism. In obesity, adipose tissue can become dysfunctional, contributing to systemic inflammation and metabolic disturbances.

Microbiome

Gut microbiota

The composition of gut microbiota is different in obese individuals compared to lean ones. The gut microbiome can influence the efficiency of energy extraction from food, inflammatory processes, and the production of short-chain fatty acids, which may affect appetite and fat storage [15].

Psychological factors

Stress and emotional eating

Stress and negative emotions can trigger overeating or preference for high-calorie comfort foods, contributing to obesity.

Sleep deprivation

Lack of sleep is associated with hormonal changes that increase appetite and cravings for unhealthy foods, leading to weight gain.

Epigenetic factors

Environmental and behavioral influence on gene expression

Epigenetic modifications, such as DNA methylation and histone modification, can alter gene expression in ways that predispose an individual to obesity. These changes can be influenced by diet, physical activity, and other environmental factors [15].

Neurobiological factors

Brain regulation of appetite

The hypothalamus plays a central role in regulating hunger and energy balance. Dysregulation in the hypothalamic circuits, often due to genetic or environmental factors, can lead to increased food intake and reduced energy expenditure, contributing to obesity [16].

Mechanisms of action

Weight loss occurs through several interconnected mechanisms, primarily involving a caloric deficit, where the body expends more energy than it consumes. This deficit forces the body to utilize stored fat as an energy source, leading to fat loss. Additionally, weight loss is influenced by hormonal changes that regulate appetite and metabolism. For instance, lower levels of insulin, a hormone that promotes fat storage, can enhance fat breakdown. Increased physical activity also plays a significant role by boosting metabolic rate and muscle mass, which in turn raises the body's energy expenditure. Furthermore, changes in diet, such as reduced carbohydrate intake, can lead to decreased insulin levels and increased fat oxidation. These combined factors contribute to overall weight loss, promoting a healthier body composition and reducing the risk of obesity-related diseases [17].

Herbal remedies for the weight loss

For many chronic conditions, including obesity, herbs have long been shown to be a vital and effective source of support. Herbs are not as harmful as single-compound medications, with the exception of a few allergic responses in those who are sensitive. Through a variety of mechanisms, including appetite suppression, triglyceride reduction, metabolic rate stimulation, inhibition of pancreatic lipase, and increased metabolic rate, medicinal herbs like green tea extract, Garcinia Cambogia, Glucomannan, Cayenne Pepper, Coleus Forskohlii and Bitter Orange (Table 2).

Current weight loss drugs

As of 2024, several weight loss drugs are available that target different mechanisms to promote weight loss. These medications are typically prescribed for individuals with obesity (BMI ≥30) or those who are overweight (BMI ≥27) with related health conditions. There are some current weight loss drugs shows in Table 3.

Orlistat

Approved for long-term use, orlistat is effective in reducing fat absorption. Clinical studies show that patients using orlistat can achieve modest weight loss (3-5% of body weight) over a year. However, its side effects, such as gastrointestinal discomfort and potential fat-soluble vitamin deficiencies, can limit its use [18].

Mechanisms of action of orlistat

Orlistat works by inhibiting gastric and pancreatic lipases, the enzymes responsible for breaking down dietary fats into absorbable forms in the intestines [19]. By blocking these enzymes, orlistat prevents the hydrolysis of triglycerides, leading to reduced fat absorption—about 30% of ingested fat is excreted undigested in the feces. This results in decreased caloric intake, promoting weight loss. Since orlistat acts locally in the gastrointestinal tract with minimal systemic absorption, it mainly affects fat absorption without influencing other nutrients.

Herb	Mechanism of Action	Common Uses	Potential Side Effects	Considerations
Green Tea Extract	Contains catechins and caffeine that may boost metabolism and increase fat oxidation.	Weight loss, metabolic boost.	Insomnia, gastrointestinal upset.	May interact with certain medications; use with caution in individuals sensitive to caffeine.
Garcinia Cambogia	Contains hydroxycitric acid (HCA) that may inhibit fat production and suppress appetite.	Appetite suppression, fat reduction.	Digestive issues, headache.	Efficacy and safety are still debated; may interact with diabetes medications.
Glucomannan	A soluble fiber that expands in the stomach to promote fullness and reduce appetite.	Appetite control, weight management.	Bloating, gas, diarrhea.	Ensure adequate hydration; may interact with medications affecting blood sugar.
Cinnamon	May improve insulin sensitivity and reduce appetite by regulating blood sugar levels.	Blood sugar control, weight management.	Allergic reactions in rare cases.	Consult a healthcare provider if taking medication for diabetes.
Cayenne Pepper	Contains capsaicin, which may increase metabolism and reduce appetite.	Metabolic boost, appetite suppression.	Gastrointestinal irritation, heartburn.	Use with caution in individuals with sensitive stomachs or gastrointestinal issues.
Coleus Forskohlii	Contains forskolin, which may aid in fat loss by increasing levels of cyclic AMP in fat cells.	Fat loss, metabolic enhancement.	Low blood pressure, digestive issues.	May interact with blood pressure medications; use with caution.
Bitter Orange	Contains synephrine, which may increase metabolism and fat oxidation.	Metabolic boost, appetite suppression.	Increased heart rate, hypertension.	Avoid in individuals with cardiovascular conditions; potential for drug interactions.

Table 2: Commonly used herbal remedies for weight loss.

Phentermine-topiramate (Qsymia)

This combination drug offers substantial weight loss (8-10% of body weight) but comes with potential risks, including increased heart rate, mood changes, and teratogenic effects. It is generally recommended for short-term use in individuals with a BMI ≥ 30 or ≥ 27 with comorbidities [20].

Mechanisms of action of phentermine-topiramate (Qsymia)

Phentermine-Topiramate (Qsymia) works through a combination of mechanisms to promote weight loss. Phentermine, a sympathomimetic agent, stimulates the release of norepinephrine in the brain, suppressing appetite and increasing energy expenditure [21]. Topiramate, originally an anticonvulsant, enhances the effects of GABA, inhibits glutamate, and blocks sodium channels, leading to reduced appetite and increased satiety. Additionally, topiramate can alter taste perception, reducing cravings for high-calorie foods. Together, these effects lead to reduced food intake and increased energy utilization, supporting weight loss.

Liraglutide (Saxenda)

Originally developed for diabetes management, liraglutide has shown effectiveness in promoting weight loss [22]. Patients may experience a 5-10% reduction in body weight, with additional benefits in glycemic control. Common side effects include nausea, vomiting, and a risk of pancreatitis.

Mechanisms of action of Liraglutide (Saxenda)

Liraglutide (Saxenda) is a GLP-1 (glucagon-like peptide-1) receptor agonist that promotes weight loss by mimicking the effects of the naturally occurring hormone GLP-1 [23]. It works by stimulating insulin secretion and reducing glucagon release, thus improving glucose metabolism and stabilizing blood sugar levels. In addition to its effects on glucose, liraglutide slows gastric emptying and increases feelings of fullness, helping to reduce overall food intake. It also acts on the hypothalamus, the brain's hunger-regulating center, to suppress appetite. These combined effects lead to reduced calorie consumption and weight loss.

Naltrexone-Bupropion (Contrave)

This combination targets appetite and reward-related eating, resulting in moderate weight loss (4-8% of body weight) [24]. However, it carries risks such as elevated blood pressure, seizure risk, and psychiatric effects, necessitating careful patient selection.

Mechanisms of action of Naltrexone-Bupropion (Contrave)

Naltrexone-Bupropion (Contrave) is a combination medication that promotes weight loss by targeting the brain's reward and appetite regulation pathways. Bupropion, an antidepressant, stimulates the release of norepinephrine and dopamine, which suppress appetite and increase energy expenditure [25]. It also acts on the hypothalamus to reduce hunger and cravings. Naltrexone, an opioid receptor antagonist, blocks opioid receptors involved in the brain's reward system, reducing the pleasure associated with eating, particularly high-calorie foods [26]. Together, these mechanisms reduce both food intake and cravings, helping individuals achieve and maintain weight loss.

Semaglutide (Wegovy)

A newer GLP-1 receptor agonist, semaglutide has demonstrated significant weight loss (up to 15% of body weight) in clinical trials [27]. It is particularly promising for patients with obesity and type 2 diabetes. Common side effects include gastrointestinal issues, and there is a need for long-term studies on safety.

Mechanisms of action Semaglutide (Wegovy)

Semaglutide (Wegovy) is a GLP-1 (glucagon-like peptide-1) receptor agonist that promotes weight loss by mimicking the action of the natural hormone GLP-1 [28]. It enhances insulin secretion while inhibiting glucagon release, leading to improved glucose control. Semaglutide also slows gastric emptying, increasing feelings of fullness and reducing overall food intake. Additionally, it acts on the appetite-regulating centers in the brain, particularly the hypothalamus, to suppress hunger and promote satiety. These combined effects lead to reduced caloric consumption and support significant weight loss in individuals using the medication.

Emerging weight loss drugs

Tirzepatide

This dual GLP-1 and GIP receptor agonist has shown remarkable efficacy in weight loss, with some studies indicating up to 20% body weight reduction [29]. It holds promise for those with severe obesity and type 2 diabetes. Ongoing trials are assessing its long-term safety and efficacy.

Mechanisms of action of Tirzepatide

Tirzepatide is a dual GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist that promotes weight loss and improves glucose metabolism. By activating both GLP-1 and GIP receptors, it enhances insulin secretion, reduces glucagon levels, and improves insulin sensitivity, leading to better blood sugar control [30]. Additionally, tirzepatide slows gastric emptying, which increases satiety and reduces food intake. Its action on the brain's appetite-regulating centers further suppresses hunger. These combined effects result in reduced caloric consumption, improved glucose regulation, and significant weight loss.

Setmelanotide

Targeting the melanocortin-4 receptor, setmelanotide is designed for patients with rare genetic obesity disorders [31]. Early results are promising, but its use will be limited to specific populations with genetic predispositions.

Mechanisms of action of Setmelanotide

Setmelanotide is a melanocortin-4 receptor (MC4R) agonist that promotes weight loss by targeting the brain's central energy balance and appetite regulation pathways. MC4R is a key part of the melanocortin system, which plays a critical role in controlling hunger and satiety [32]. By activating MC4R, setmelanotide reduces appetite and increases energy expenditure. It is particularly effective in individuals with rare genetic disorders, such as POMC, LEPR, or PCSK1 deficiencies, where the melanocortin pathway is disrupted. Through its action on MC4R, setmelanotide helps restore normal appetite control, leading to reduced food intake and weight loss.

Table 3: Anti-obesity drugs, including their mechanisms of action, primary uses, common side effects [18].

Drug	Mechanism of Action	Primary Use	Common Side Effects	Considerations
Orlistat	Inhibits pancreatic and gastric lipases, reducing fat absorption.	Weight loss and management in obesity.	Fatty stools, diarrhea, abdominal pain.	May require supplementation of fat-soluble vitamins.
Phentermine-Topiramate	Phentermine suppresses appetite by increasing norepinephrine; Topiramate reduces appetite through multiple pathways.	Short-term weight loss in obesity; combination for sustained weight loss.	Dry mouth, constipation, insomnia, dizziness.	Monitor for potential psychiatric side effects and avoid use in individuals with a history of substance abuse.
Liraglutide (Saxenda)	Mimics GLP-1 to enhance insulin secretion, slow gastric emptying, and increase satiety.	Weight loss and management in obesity and type 2 diabetes.	Nausea, diarrhea, constipation, headache.	Monitor for potential thyroid issues and pancreatitis.
Naltrexone-Bupropion	Bupropion increases norepinephrine and dopamine release; Naltrexone blocks opioid receptors reducing cravings.	Weight loss and management in obesity and depression.	Nausea, headache, insomnia, dry mouth.	Caution in patients with seizures, eating disorders, or hypertension.
Semaglutide (Wegovy)	Mimics GLP-1 to enhance insulin secretion, inhibit glucagon, slow gastric emptying, and increase satiety.	Weight loss in obesity and overweight conditions.	Nausea, vomiting, diarrhea, abdominal pain.	Potential risk of thyroid tumors and pancreatitis; monitor for gastrointestinal symptoms.
Tirzepatide	Dual GLP-1 and GIP receptor agonist; enhances insulin secretion, improves glucose control, slows gastric emptying, and reduces appetite.	Weight loss and management in obesity and type 2 diabetes.	Nausea, diarrhea, vomiting, decreased appetite.	Monitor for gastrointestinal issues and assess for potential thyroid concerns.
Setmelanotide	Agonizes MC4R to restore appetite control and increase energy expenditure.	Weight loss in genetic obesity disorders (e.g., POMC, LEPR deficiencies).	Injection site reactions, nausea, fatigue.	Effective mainly in genetic disorders; requires genetic testing for eligibility.

Conclusion

Obesity remains a critical global health challenge with significant implications for both physical and mental health. The multifactorial nature of obesity, influenced by genetic, environmental, and behavioral factors, makes it difficult to manage. Traditional approaches, including lifestyle modifications and behavioral therapy, are essential but often insufficient for long-term success in many individuals. Pharmacological interventions, while effective, come with limitations such as side effects and varying efficacy among patients.

Recent advances in pharmacotherapy have provided hope for more sustainable obesity management. Emerging drugs, such as GLP-1 receptor agonists and dual-acting medications like tirzepatide, offer new mechanisms of action and show promising results in weight reduction. However, continued research is necessary to assess their long-term safety and efficacy. Moving forward, personalized treatment approaches that integrate lifestyle modifications, psychological support, and pharmacotherapy may be the key to addressing the obesity epidemic effectively.

Bibliography

1. Mohajan D and Mohajan HK. "Obesity and its related diseases: a new escalating alarming in global health". *Journal of Innovations in Medical Research* 2.3 (2023): 12-23.

2. Goossens GH. "The metabolic phenotype in obesity: fat mass, body fat distribution, and adipose tissue function". *Obesity Facts* 10.3 (2017): 207-215.

3. Tomic D., *et al*. "The burden and risks of emerging complications of diabetes mellitus". *Nature Reviews Endocrinology* 18.9 (2022): 525-539.

4. Lim HJ., *et al*. "Global trends in obesity". Handbook of Eating and Drinking: Interdisciplinary Perspectives. (2020): 1217-1235.

5. Malik VS., *et al*. "Global obesity: trends, risk factors and policy implications". *Nature Reviews Endocrinology* 9.1 (2013): 13-27.

6. Hojjat TA and Hojatt R. "Economics of obesity". Springer (2021).

7. Wadden TA., *et al*. "Lifestyle modification approaches for the treatment of obesity in adults". *American Psychologist* 75.2 (2020): 235.

8. Dinda B. "Clinical Trials of Phytomedicines in the Management of Obesity and Diabetes". In: Natural Products in Obesity and Diabetes: Therapeutic Potential and Role in Prevention and Treatment. Springer (2022): 533-51.

9. Argenio KL., *et al*. "Increasing disparities in obesity and severe obesity prevalence among public elementary and middle school students in New York City, school years 2011-12 through 2019-20". *Plos One* 19.5 (2024): e0302099.

10. Speakman JR. "Obesity: the integrated roles of environment and genetics". *The Journal of Nutrition* 134.8 (2004): 2090S-2105S.

11. Dubern B and Clement K. "Leptin and leptin receptor-related monogenic obesity". *Biochimie* 94.10 (2012): 2111-2115.

12. Hinney A., *et al*. "From monogenic to polygenic obesity: recent advances". *European Child and Adolescent Psychiatry 19* (2010): 297-310.

13. Matafome P and Seiça R. "The role of brain in energy balance". *Obesity and Brain Function* (2017): 33-48.

14. Schmid DA., *et al*. "Ghrelin stimulates appetite, imagination of food, GH, ACTH, and cortisol, but does not affect leptin in normal controls". *Neuropsychopharmacology* 30.6 (2005): 1187-1192.

15. Blaut M. "Gut microbiota and energy balance: role in obesity". *Proceedings of the Nutrition Society* 74.3 (2015): 227-234.

16. Rui L. "Brain regulation of energy balance and body weight". *Reviews in Endocrine and Metabolic Disorders* 14 (2013): 387-407.

17. Solomon TPJ., *et al*. "Exercise and diet enhance fat oxidation and reduce insulin resistance in older obese adults". *Journal of Applied Physiology* (2008).

18. Tak YJ and Lee SY. "Anti-obesity drugs: long-term efficacy and safety: an updated review". *The World Journal of Men's Health* 39.2 (2021): 208.

19. Rajan L., *et al*. "Targeting obesity with plant-derived pancreatic lipase inhibitors: A comprehensive review". *Pharmacological Research* 155 (2020): 104681.

20. Jordan MA. "Interactions with drugs and dietary supplements used for weight loss". In: Drug discovery. IntechOpen (2013).

21. Bray GA. "A concise review on the therapeutics of obesity". *Nutrition* 16.10 (2000): 953-960.

22. Ladenheim EE. "Liraglutide and obesity: a review of the data so far". *Drug Design, Development and Therapy* (2015): 1867-1875.

23. Prasad-Reddy L and Isaacs D. "A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond". *Drugs in Context* (2015): 4.

24. Billes SK., *et al*. "Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss". *Pharmacological Research* 84 (2014): 1-11.

25. Patel K., *et al*. "Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant". *Therapeutic Advances in psychopharmacology* 6.2 (2016): 99-144.

26. Cambridge VC., *et al*. "Neural and behavioral effects of a novel mu opioid receptor antagonist in binge-eating obese people". *Biological Psychiatry* 73.9 (2013): 887-894.

27. Singh G., *et al*. "Wegovy (semaglutide): a new weight loss drug for chronic weight management". *Journal of Investigative Medicine* 70.1 (2022): 5-13.

28. Moore PW., *et al*. "GLP-1 agonists for weight loss: pharmacology and clinical implications". *Advances in Therapy* 40.3 (2023): 723-742.

29. Min T and Bain SC. "The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: the SURPASS clinical trials". *Diabetes Therapy* 12.1 (2021): 143-157.

30. Fisman EZ., *et al*. "The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect". *Cardiovascular Diabetology* 20.1 (2021): 225.

31. Haws R., *et al*. "Effect of setmelanotide, a melanocortin-4 receptor agonist, on obesity in Bardet-Biedl syndrome". *Diabetes, Obesity and Metabolism* 22.11 (2020): 2133-2140.

32. Yeo GSH., *et al*. "The melanocortin pathway and energy homeostasis: From discovery to obesity therapy". *Molecular Metabolism* 48 (2021): 101206.